ArticleCureus2026
N4-Acetyl-Sulfamethoxazole Bladder Stones Caused by Trimethoprim-Sulfamethoxazole Prophylaxis: A Report of Two Cases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination antimicrobial trimethoprim-sulfamethoxazole (TMP-SMX) has a broad spectrum of activity and is used as a prophylactic for various infections. Drug-induced urolithiasis is a rare side effect of TMP-SMX that results from the precipitation of its metabolite N4-acetyl-sulfamethoxazole. There are only two reports of bladder stones associated with TMP-SMX, both of which occurred in patients with a history of recurrent urinary tract infections (UTIs). At our institution, an 80-year-old male with a complex medical history including benign prostatic hyperplasia (BPH) and a chronic prosthetic joint infection on long-term amoxicillin and TMP-SMX presented for evaluation of an incidental 2.4 cm bladder stone. Surgical intervention was initially deferred due to patient preference, but he later developed gross hematuria and decided to undergo cystoscopy with cystolitholapaxy and bilateral retrograde pyelogram. The procedure was completed without complications. Analysis of stone fragments revealed that they were 100% N4-acetyl-sulfamethoxazole. Months later, a 70-year-old male with multiple sclerosis and neurogenic bladder complicated by recurrent UTIs managed with a suprapubic catheter and TMP-SMX prophylaxis was found to have multiple bladder stones causing obstructive symptoms. These stones were similarly treated with cystolitholapaxy and identified as 100% N4-acetyl-sulfamethoxazole. Bladder stones caused by TMP-SMX have been rarely reported in people like our 70-year-old patient with an abnormal urinary metabolic profile, indicated by a history of urolithiasis or UTIs. Our other patient did not have either of these risk factors, but he did have lower urinary tract symptoms due to BPH. His case may serve as a caution to the use of TMP-SMX in the setting of chronic urinary stasis due to bladder outlet obstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.